Sally Nneoma Adebamowo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sally Nneoma Adebamowo has a total of 298 co-authors. Here are the top co-authors by number of shared publications:
- Clement Adebamowo
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, USA
44 shared publications - Adeola Akintola
Department of Research Center for Bioethics and Research Ibadan Nigeria
11 shared publications - Shawneequa Callier
Department of Clinical Research and Leadership School of Medicine and Health Sciences, The George Washington University Washington DC USA
11 shared publications - Temidayo Ogundiran
Department of Bioethics and Medical Humanities Faculty of Multidisciplinary Studies, University of Ibadan Ibadan Nigeria
11 shared publications - Ayodele Samuel Jegede
Department of Sociology, University of Ibadan
10 shared publications Olayinka Olaniyan
National Hospital Abuja, Abuja, Nigeria
10 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Wiley in Developing World Bioethics
Yoruba Moral Philosophy and the Ethical Governance of Data Science Health Research in Africa
Data science health research (DSHR) which encompasses genomic biobanking, algorithmic clinical prediction, large‐scale secondary use of health data, and AI‐assisted diagnostics is expanding rapidly across Africa through initiatives such as the Human Heredity and Health in Africa (H3Africa) consortium and the Data Science for Health Discovery and Innovation in Africa (DS‐I Africa) program. Existing ethical governance frameworks based on Western principlism, Ubuntu‐based bioethics, and the CARE Principles for Indigenous Data Governance each capture part of the ethical terrain for governance of DSHR in Africa but gaps remain. In this paper, we apply a Yoruba moral philosophical framework, developed in a companion paper, to the five central challenges of DSHR governance in Yoruba communities: informed consent in big‐data contexts, algorithmic fairness, data sovereignty, secondary use of health data, and AI clinical decision support. Drawing on the six Yoruba moral principles that extend principlism including procedural communal deliberation ( Ifọgbọntáayésé ), moderate‐communitarian relational personhood, virtue‐based character ethics ( Ìwà/Omolúàbí ), intergenerational kinship obligations ( Àjọbí ), sacred‐epistemic confidentiality ( Awo ), and restorative‐adjudicative justice ( Ìlàjà ), we demonstrate that each generates concrete, operationalizable governance recommendations that exceed what principlism, Ubuntu‐bioethics, or CARE Principles supply individually. We present a comprehensive governance framework with specific institutional mechanisms: Community Data Stewardship Councils, tiered consent with lineage‐level governance, Omolúàbí‐ informed researcher assessment, ẹbọ ‐based benefit‐sharing, Awo ‐governed data classification, and ìlàjà restorative harm remediation. The framework positions Yoruba moral philosophy as one voice in a principled pluralism for the ethical governance of DSHR in Africa. It is designed to operate within, not alongside, the harmonized procedures and instruments, supplying locally grounded moral content at the points where those instruments require community engagement but leave its form unspecified. It is not a replacement for existing approaches but a substantive addition to the current governance landscape.
- 28 October 2026
- Published by Wiley in Developing World Bioethics
Open AccessYoruba Moral Philosophy and the Ethical Governance of Data Science Health Research in Africa
Data science health research (DSHR) which encompasses genomic biobanking, algorithmic clinical prediction, large‐scale secondary use of health data, and AI‐assisted diagnostics is expanding rapidly across Africa through initiatives such as the Human Heredity and Health in Africa (H3Africa) consortium and the Data Science for Health Discovery and Innovation in Africa (DS‐I Africa) program. Existing ethical governance frameworks based on Western principlism, Ubuntu‐based bioethics, and the CARE Principles for Indigenous Data Governance each capture part of the ethical terrain for governance of DSHR in Africa but gaps remain. In this paper, we apply a Yoruba moral philosophical framework, developed in a companion paper, to the five central challenges of DSHR governance in Yoruba communities: informed consent in big‐data contexts, algorithmic fairness, data sovereignty, secondary use of health data, and AI clinical decision support. Drawing on the six Yoruba moral principles that extend principlism including procedural communal deliberation ( Ifọgbọntáayésé ), moderate‐communitarian relational personhood, virtue‐based character ethics ( Ìwà/Omolúàbí ), intergenerational kinship obligations ( Àjọbí ), sacred‐epistemic confidentiality ( Awo ), and restorative‐adjudicative justice ( Ìlàjà ), we demonstrate that each generates concrete, operationalizable governance recommendations that exceed what principlism, Ubuntu‐bioethics, or CARE Principles supply individually. We present a comprehensive governance framework with specific institutional mechanisms: Community Data Stewardship Councils, tiered consent with lineage‐level governance, Omolúàbí‐ informed researcher assessment, ẹbọ ‐based benefit‐sharing, Awo ‐governed data classification, and ìlàjà restorative harm remediation. The framework positions Yoruba moral philosophy as one voice in a principled pluralism for the ethical governance of DSHR in Africa. It is designed to operate within, not alongside, the harmonized procedures and instruments, supplying locally grounded moral content at the points where those instruments require community engagement but leave its form unspecified. It is not a replacement for existing approaches but a substantive addition to the current governance landscape.
- Open Access
- 29 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e99980
Dissolution of Continuity of Ethical Governance in Data Science Health Research: Diagnostic and Response Framework for Lifecycle Oversight
Traditional research ethics governance was designed for bounded protocols, identifiable investigators, and temporally limited encounters with human participants. Data science health research (DSHR) disrupts that architecture because health data, biological materials, computational representations, and models persist, travel, combine, and acquire new uses across time. In this viewpoint, we use DSHR broadly to include research using large health datasets and adjacent secondary uses of health data, models, and biological materials, including learning health systems, public health surveillance, quality improvement, operations, commercial product development, and artificial intelligence (AI)–enabled translational uses that rely on health data or material lineages. We introduce ethical governance continuity dissolution (EGCD), the progressive and sometimes irreversible loss of domain-specific governance authority across a data, model, or biological material lineage, such that no coherent set of actors, instruments, or community processes can authorize, constrain, monitor, adjudicate, or remediate current use in relation to the persons and communities of origin. EGCD is distinct from consent staleness, function creep, contextual integrity violation, algorithmic drift, or a single defective data use agreement. It is the systemic condition in which several such failures together compromise the authority needed to govern current use. Building on our prior work on representational veracity and the continuity trap, we propose a diagnostic architecture that assesses six governance authority domains, applies three diagnostic criteria, scores each domain from 0 to 3 within a Continuity Authority Matrix (CAM), and stages severity from 0 to 4. We also propose an Ethical Continuity Governance and Response Mechanism (ECGRM) comprising a continuity registry, the CAM, trigger-based review, a Data Lifecycle Governance Officer function, a Continuity Dissolution Review Board, corrective and preventive action, cross-institutional audit, and community-governance integration. We use a publicly reported Royal Free–DeepMind Streams example to show how domain scores can identify stage 2 or 3 risk without converting the framework into a retrospective legal judgment. Implementation is proportionate, so these functions may operate within existing structures, particularly in underresourced institutions. The score and staging thresholds are conceptual triage aids, not validated metrics or automated determinations of ethical permissibility, and they require empirical validation and interrater reliability testing. Their purpose is to prevent the silent loss of governance authority while data, models, and biological materials continue to affect the lives, identities, and community standing of the persons and groups from whom they were derived. Lawful public health surveillance under a competent authority is a legitimate governance handoff, not EGCD; EGCD arises when authority is not transferred, traceable, accountable, or remediable. This viewpoint is addressed to research ethics committees and institutional review boards, data access committees, data stewards, biobank and registry leaders, AI governance teams, regulators, funders, community governance bodies, and investigators.
- 29 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e99980
Open AccessDissolution of Continuity of Ethical Governance in Data Science Health Research: Diagnostic and Response Framework for Lifecycle Oversight
Traditional research ethics governance was designed for bounded protocols, identifiable investigators, and temporally limited encounters with human participants. Data science health research (DSHR) disrupts that architecture because health data, biological materials, computational representations, and models persist, travel, combine, and acquire new uses across time. In this viewpoint, we use DSHR broadly to include research using large health datasets and adjacent secondary uses of health data, models, and biological materials, including learning health systems, public health surveillance, quality improvement, operations, commercial product development, and artificial intelligence (AI)–enabled translational uses that rely on health data or material lineages. We introduce ethical governance continuity dissolution (EGCD), the progressive and sometimes irreversible loss of domain-specific governance authority across a data, model, or biological material lineage, such that no coherent set of actors, instruments, or community processes can authorize, constrain, monitor, adjudicate, or remediate current use in relation to the persons and communities of origin. EGCD is distinct from consent staleness, function creep, contextual integrity violation, algorithmic drift, or a single defective data use agreement. It is the systemic condition in which several such failures together compromise the authority needed to govern current use. Building on our prior work on representational veracity and the continuity trap, we propose a diagnostic architecture that assesses six governance authority domains, applies three diagnostic criteria, scores each domain from 0 to 3 within a Continuity Authority Matrix (CAM), and stages severity from 0 to 4. We also propose an Ethical Continuity Governance and Response Mechanism (ECGRM) comprising a continuity registry, the CAM, trigger-based review, a Data Lifecycle Governance Officer function, a Continuity Dissolution Review Board, corrective and preventive action, cross-institutional audit, and community-governance integration. We use a publicly reported Royal Free–DeepMind Streams example to show how domain scores can identify stage 2 or 3 risk without converting the framework into a retrospective legal judgment. Implementation is proportionate, so these functions may operate within existing structures, particularly in underresourced institutions. The score and staging thresholds are conceptual triage aids, not validated metrics or automated determinations of ethical permissibility, and they require empirical validation and interrater reliability testing. Their purpose is to prevent the silent loss of governance authority while data, models, and biological materials continue to affect the lives, identities, and community standing of the persons and groups from whom they were derived. Lawful public health surveillance under a competent authority is a legitimate governance handoff, not EGCD; EGCD arises when authority is not transferred, traceable, accountable, or remediable. This viewpoint is addressed to research ethics committees and institutional review boards, data access committees, data stewards, biobank and registry leaders, AI governance teams, regulators, funders, community governance bodies, and investigators.
- Open Access
- 11 September 2026
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (20)
Pleiotropy and eQTL analysis identify shared genetic architecture of lipid traits in African-ancestry populations
Dyslipidemia is a leading modifiable risk factor for cardiovascular disease (CVD), yet the shared genetic architecture of lipid traits remains poorly characterized, particularly in African-ancestry populations who bear a disproportionate CVD burden but are underrepresented in genomic research. We conducted multi-trait meta-analyses of genome-wide association summary statistics for HDL cholesterol, LDL cholesterol, triglycerides, and total cholesterol in 34 039 individuals of African ancestry, comprising 27 289 discovery participants from three continental African cohorts (ACCME, AWI-Gen, and UGR) and 6750 replication participants from the UK Biobank. Multi-trait analysis and eQTL colocalization across metabolic and cardiovascular tissues were then performed to identify shared genetic signals and characterize their tissue-specific regulatory mechanisms. Multi-trait analysis identified 90 genome-wide significant variants. Of these, 43 were novel variants with no prior exact-variant lipid association records. Eight variants across six genomic regions reached genome-wide significance in the multi-trait analysis and 70 of the 90 primary signals remained significant after total cholesterol was excluded. The strongest associations localized to established lipid loci including APOE/NECTIN2/TOMM40 (P = 8.09 × 10−133), CETP (P = 9.44 × 10−108), LIPC (P = 9.42 × 10−51), and LPL (P = 5.79 × 10−22), with 92% of signals replicating in the UK Biobank cohort. eQTL colocalization linked seven lead variants to tissue-specific gene expression and prioritized candidate regulatory genes. Together, these findings characterize shared lipid-associated signals with heterogeneous, trait-dependent effects in continental African populations and provide population-relevant evidence for candidate regulatory mechanisms.
- 11 September 2026
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (20)
Open AccessPleiotropy and eQTL analysis identify shared genetic architecture of lipid traits in African-ancestry populations
Dyslipidemia is a leading modifiable risk factor for cardiovascular disease (CVD), yet the shared genetic architecture of lipid traits remains poorly characterized, particularly in African-ancestry populations who bear a disproportionate CVD burden but are underrepresented in genomic research. We conducted multi-trait meta-analyses of genome-wide association summary statistics for HDL cholesterol, LDL cholesterol, triglycerides, and total cholesterol in 34 039 individuals of African ancestry, comprising 27 289 discovery participants from three continental African cohorts (ACCME, AWI-Gen, and UGR) and 6750 replication participants from the UK Biobank. Multi-trait analysis and eQTL colocalization across metabolic and cardiovascular tissues were then performed to identify shared genetic signals and characterize their tissue-specific regulatory mechanisms. Multi-trait analysis identified 90 genome-wide significant variants. Of these, 43 were novel variants with no prior exact-variant lipid association records. Eight variants across six genomic regions reached genome-wide significance in the multi-trait analysis and 70 of the 90 primary signals remained significant after total cholesterol was excluded. The strongest associations localized to established lipid loci including APOE/NECTIN2/TOMM40 (P = 8.09 × 10−133), CETP (P = 9.44 × 10−108), LIPC (P = 9.42 × 10−51), and LPL (P = 5.79 × 10−22), with 92% of signals replicating in the UK Biobank cohort. eQTL colocalization linked seven lead variants to tissue-specific gene expression and prioritized candidate regulatory genes. Together, these findings characterize shared lipid-associated signals with heterogeneous, trait-dependent effects in continental African populations and provide population-relevant evidence for candidate regulatory mechanisms.
- Open Access
- 2 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e102537
Representational Veracity in Data Science Health Research: Targets, Proxies, Labels, and Descriptors
Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because each presupposes an answer to a prior question that is seldom asked directly. That is, “do the targets, proxies, labels, classifications, ontologies, and population descriptors on which a current study rests still truthfully represent the persons, populations, and phenomena they are taken to describe, at the point of use rather than the point of collection?” In this viewpoint, we name that question representational veracity (RV) and develop it as a construct for upstream ethical review. Our aims are to define RV and derive the domains along which it can be assessed; to demonstrate that it asks something that measurement validity, critical data studies, and algorithmic fairness do not; and to translate it into instruments that review bodies can use. We derive 4 assessment domains of RV analytically, asking for each transition in the data journey what must remain stable for a stored artifact still to stand for what it originally stood for. The resulting domains are material provenance, informational descriptors, normative authorization, and relational community. These domains interact but do not substitute for one another. Intact provenance cannot repair a poorly chosen target, and a transparent labeling process cannot confer authorization it never had. Drawing on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health AI governance, we show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, too unstable, or too normatively misdirected for the proposed use. We examine 4 recurrent failure modes, proxy substitution, category misassignment, label generation error, and descriptor sedimentation, anchoring each in a published case, and we present a counterpoint in which better representation reveals rather than conceals inequity. A polygenic risk score (PRS) case study illustrates all 4 domains and shows how a score can misclassify risk in the populations least represented in its derivation while its code, pipeline, and internal validation statistics remain intact. We then translate the framework into practice using 10 reviewer prompts that an editor can paste into a review form, a justification template and scoring rubric provided as appendices, a tiered model that triggers full review only for subgroup, equity, transportability, public health, or clinical implementation claims, and a graded account of what should follow an adverse finding. Our argument is that existing governance mechanisms require an upstream layer. Investigators should be asked to justify not only whether their models perform, but whether their representations are truthful enough for the claims at hand. The intended audience is investigators, informaticians, research ethics committees, institutional review boards, data access committees, funders, regulators, and journal editors.
- 2 September 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e102537
Open AccessRepresentational Veracity in Data Science Health Research: Targets, Proxies, Labels, and Descriptors
Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because each presupposes an answer to a prior question that is seldom asked directly. That is, “do the targets, proxies, labels, classifications, ontologies, and population descriptors on which a current study rests still truthfully represent the persons, populations, and phenomena they are taken to describe, at the point of use rather than the point of collection?” In this viewpoint, we name that question representational veracity (RV) and develop it as a construct for upstream ethical review. Our aims are to define RV and derive the domains along which it can be assessed; to demonstrate that it asks something that measurement validity, critical data studies, and algorithmic fairness do not; and to translate it into instruments that review bodies can use. We derive 4 assessment domains of RV analytically, asking for each transition in the data journey what must remain stable for a stored artifact still to stand for what it originally stood for. The resulting domains are material provenance, informational descriptors, normative authorization, and relational community. These domains interact but do not substitute for one another. Intact provenance cannot repair a poorly chosen target, and a transparent labeling process cannot confer authorization it never had. Drawing on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health AI governance, we show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, too unstable, or too normatively misdirected for the proposed use. We examine 4 recurrent failure modes, proxy substitution, category misassignment, label generation error, and descriptor sedimentation, anchoring each in a published case, and we present a counterpoint in which better representation reveals rather than conceals inequity. A polygenic risk score (PRS) case study illustrates all 4 domains and shows how a score can misclassify risk in the populations least represented in its derivation while its code, pipeline, and internal validation statistics remain intact. We then translate the framework into practice using 10 reviewer prompts that an editor can paste into a review form, a justification template and scoring rubric provided as appendices, a tiered model that triggers full review only for subgroup, equity, transportability, public health, or clinical implementation claims, and a graded account of what should follow an adverse finding. Our argument is that existing governance mechanisms require an upstream layer. Investigators should be asked to justify not only whether their models perform, but whether their representations are truthful enough for the claims at hand. The intended audience is investigators, informaticians, research ethics committees, institutional review boards, data access committees, funders, regulators, and journal editors.
- Open Access
- 19 August 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e98699
The Continuity Trap in Data Science Health Research
Secondary use is now the ordinary condition of data science health research rather than an exception to it. Electronic health records collected for clinical care become prediction tools and inputs for generative AI; imaging archives become foundation-model corpora; genomic datasets become resources for polygenic risk scores; and legacy biospecimens become renewable, indefinitely distributable cell lines. Governance has responded by emphasizing verifiable instruments such as provenance logs, repository approvals, broad-consent forms, data-use agreements, model cards, records of processing, and locality-preserving architectures. These instruments are necessary, and they answer real questions about lineage, privacy, institutional responsibility, and accountability, but they are not sufficient to establish that a present use remains ethically justified. We define ethical continuity as the persistence of normatively relevant relationships between the original conditions of data generation or material collection and subsequent downstream uses, such that current uses remain justifiable in light of the expectations, permissions, meanings, and relational obligations present at entrustment. We then define the Continuity Trap as a review-stage governance error in which a salient signal of continuity in one domain is treated as sufficient evidence of ethical continuity overall, causing inquiry into the remaining domains to close prematurely. The trap is not ordinary noncompliance, ethics creep, or a demand for universal rereview; it is a cross-domain inference error that can arise even in careful, good-faith review. We distinguish it from proxy closure, of which it is a continuity-specific subtype, and from Goodhart’s and Campbell’s laws, which describe how measures degrade once they become targets. We operationalize ethical continuity across 4 domains: provenance, semantics, authorization, and relational standing, developed in our Representational Veracity framework, and we show that these domains can diverge as data are linked, transformed, modeled, and redeployed. We identify the institutional mechanisms—provenance privilege, descriptor sedimentation, authorization fossilization, and community effacement—that cause auditable signals to be overread, and we examine how the US Health Insurance Portability and Accountability Act (HIPAA) of 1996, the General Data Protection Regulation, the European Health Data Space, US Food and Drug Administration guidance, the US National Institute of Standards and Technology (NIST) AI Risk Management Framework, and federated-learning governance can reduce risk while still inducing continuity traps. We apply the framework to consent and nonconsent settings, including public health, immunization, syndromic, and wastewater surveillance, polygenic risk scores, induced pluripotent stem cells, federated learning, and health-related large language models. The policy implication is trigger-based continuity review: rather than rereviewing every reuse, investigators and reviewers should identify the weakest continuity domain at the present data stage and impose a domain-matched safeguard, recorded in a short continuity statement. This reframing is intended for the committees, repositories, funders, and governance bodies that decide whether reuse may proceed, and it matters most in cross-border and low-resource settings. Provenance should begin ethical review; it should not end it.
- 19 August 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e98699
Open AccessThe Continuity Trap in Data Science Health Research
Secondary use is now the ordinary condition of data science health research rather than an exception to it. Electronic health records collected for clinical care become prediction tools and inputs for generative AI; imaging archives become foundation-model corpora; genomic datasets become resources for polygenic risk scores; and legacy biospecimens become renewable, indefinitely distributable cell lines. Governance has responded by emphasizing verifiable instruments such as provenance logs, repository approvals, broad-consent forms, data-use agreements, model cards, records of processing, and locality-preserving architectures. These instruments are necessary, and they answer real questions about lineage, privacy, institutional responsibility, and accountability, but they are not sufficient to establish that a present use remains ethically justified. We define ethical continuity as the persistence of normatively relevant relationships between the original conditions of data generation or material collection and subsequent downstream uses, such that current uses remain justifiable in light of the expectations, permissions, meanings, and relational obligations present at entrustment. We then define the Continuity Trap as a review-stage governance error in which a salient signal of continuity in one domain is treated as sufficient evidence of ethical continuity overall, causing inquiry into the remaining domains to close prematurely. The trap is not ordinary noncompliance, ethics creep, or a demand for universal rereview; it is a cross-domain inference error that can arise even in careful, good-faith review. We distinguish it from proxy closure, of which it is a continuity-specific subtype, and from Goodhart’s and Campbell’s laws, which describe how measures degrade once they become targets. We operationalize ethical continuity across 4 domains: provenance, semantics, authorization, and relational standing, developed in our Representational Veracity framework, and we show that these domains can diverge as data are linked, transformed, modeled, and redeployed. We identify the institutional mechanisms—provenance privilege, descriptor sedimentation, authorization fossilization, and community effacement—that cause auditable signals to be overread, and we examine how the US Health Insurance Portability and Accountability Act (HIPAA) of 1996, the General Data Protection Regulation, the European Health Data Space, US Food and Drug Administration guidance, the US National Institute of Standards and Technology (NIST) AI Risk Management Framework, and federated-learning governance can reduce risk while still inducing continuity traps. We apply the framework to consent and nonconsent settings, including public health, immunization, syndromic, and wastewater surveillance, polygenic risk scores, induced pluripotent stem cells, federated learning, and health-related large language models. The policy implication is trigger-based continuity review: rather than rereviewing every reuse, investigators and reviewers should identify the weakest continuity domain at the present data stage and impose a domain-matched safeguard, recorded in a short continuity statement. This reframing is intended for the committees, repositories, funders, and governance bodies that decide whether reuse may proceed, and it matters most in cross-border and low-resource settings. Provenance should begin ethical review; it should not end it.
- Open Access
- 17 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
The Implicit Assumption in Transplanted Ethics: Informed Consent, Unequal Protective Force, and Accountability Ecology (Preprint)
UNSTRUCTURED Informed consent remains ethically indispensable, but it is often treated as if the procedures alone deliver equivalent participant protection across research settings. We argue that consent has unequal protective force because its effectiveness depends on two unevenly distributed conditions - the material conditions that make refusal substantively possible and an accountability ecology that converts ethical breakdown into deterrence, remedy, and institutional learning. Focusing on the latter, we identify four components - financial-institutional incentives, legal-adjudicatory recourse, political accountability and public revisability, and public contestability. We illustrate the framework with three cases, Ellen Roche at Johns Hopkins, the Kano/Trovan controversy, and India’s HPV demonstration projects, to show how variation in the latency, density, and enforceability of accountability alters what otherwise similar consent procedures can protect. The result is not a case against consent, but against assuming that transplanted procedures carry equivalent protective force.
- 17 August 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Implicit Assumption in Transplanted Ethics: Informed Consent, Unequal Protective Force, and Accountability Ecology (Preprint)
UNSTRUCTURED Informed consent remains ethically indispensable, but it is often treated as if the procedures alone deliver equivalent participant protection across research settings. We argue that consent has unequal protective force because its effectiveness depends on two unevenly distributed conditions - the material conditions that make refusal substantively possible and an accountability ecology that converts ethical breakdown into deterrence, remedy, and institutional learning. Focusing on the latter, we identify four components - financial-institutional incentives, legal-adjudicatory recourse, political accountability and public revisability, and public contestability. We illustrate the framework with three cases, Ellen Roche at Johns Hopkins, the Kano/Trovan controversy, and India’s HPV demonstration projects, to show how variation in the latency, density, and enforceability of accountability alters what otherwise similar consent procedures can protect. The result is not a case against consent, but against assuming that transplanted procedures carry equivalent protective force.
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
A Persistence-Based Ethical Governance Framework for Data Science Health Research
Banked datasets are increasingly reused for data-science health research years or decades after collection, yet existing ethics frameworks focus on privacy and consent without assessing whether stored data continue to accurately and legitimately represent the persons and communities from whom they originate. We define representational veracity (RV) as the fidelity of stored data to the evolving identity, descriptors, and normative expectations of data sources at the point of use. Drawing on philosophical accounts of persistence through time, we distinguish material continuity from normative continuity and identify four domains where representational adequacy can degrade: material provenance, informational descriptors, normative authorization, and relational community. We translate this analysis into an operational governance framework comprising a structured assessment matrix, triggers for heightened review, and documentation standards for research ethics and data-access committees. The framework is illustrated through genomics and data-science case vignettes, with particular attention to equity implications for historically marginalized populations.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Persistence-Based Ethical Governance Framework for Data Science Health Research
Banked datasets are increasingly reused for data-science health research years or decades after collection, yet existing ethics frameworks focus on privacy and consent without assessing whether stored data continue to accurately and legitimately represent the persons and communities from whom they originate. We define representational veracity (RV) as the fidelity of stored data to the evolving identity, descriptors, and normative expectations of data sources at the point of use. Drawing on philosophical accounts of persistence through time, we distinguish material continuity from normative continuity and identify four domains where representational adequacy can degrade: material provenance, informational descriptors, normative authorization, and relational community. We translate this analysis into an operational governance framework comprising a structured assessment matrix, triggers for heightened review, and documentation standards for research ethics and data-access committees. The framework is illustrated through genomics and data-science case vignettes, with particular attention to equity implications for historically marginalized populations.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 46 (3) , e519768
Global Cancer Prevention: Current Approaches and Future Directions
Cancer is a leading and growing cause of morbidity and mortality worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022 and projections of substantially greater burden over coming decades. A large fraction of this burden is preventable through interventions directed at established modifiable risk factors, including tobacco, excess body weight, alcohol, ultraviolet and occupational exposures, and oncogenic infections such as human papillomavirus (HPV) and hepatitis B virus. Yet, primary prevention remains underutilized relative to its demonstrated impact. In this chapter, derived from presentations at the 2026 ASCO Annual Meeting Education Session on global cancer prevention, we synthesize the contemporary global burden of preventable cancers quantified through population attributable fractions; summarize progress and remaining challenges in eliminating cervical cancer through HPV vaccination, screening, and treatment of precancerous lesions; and examine evidence-based approaches to cancer control in Africa, where the preventable fraction is particularly high. We conclude with priority actions spanning policy, financing, workforce development, and research that are needed to translate the existing prevention evidence base into measurable reductions in cancer incidence and mortality, particularly in settings of greatest need.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 46 (3) , e519768
Global Cancer Prevention: Current Approaches and Future Directions
Cancer is a leading and growing cause of morbidity and mortality worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022 and projections of substantially greater burden over coming decades. A large fraction of this burden is preventable through interventions directed at established modifiable risk factors, including tobacco, excess body weight, alcohol, ultraviolet and occupational exposures, and oncogenic infections such as human papillomavirus (HPV) and hepatitis B virus. Yet, primary prevention remains underutilized relative to its demonstrated impact. In this chapter, derived from presentations at the 2026 ASCO Annual Meeting Education Session on global cancer prevention, we synthesize the contemporary global burden of preventable cancers quantified through population attributable fractions; summarize progress and remaining challenges in eliminating cervical cancer through HPV vaccination, screening, and treatment of precancerous lesions; and examine evidence-based approaches to cancer control in Africa, where the preventable fraction is particularly high. We conclude with priority actions spanning policy, financing, workforce development, and research that are needed to translate the existing prevention evidence base into measurable reductions in cancer incidence and mortality, particularly in settings of greatest need.
- Open Access
- 26 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Representational Veracity in Data Science Health Research: A Companion Viewpoint on Targets, Proxies, Labels, and Descriptors (Preprint)
UNSTRUCTURED Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because they presuppose that the targets, proxies, labels, classifications, ontologies, and population descriptors already truthfully represent the populations and phenomena they claim to describe. That prior question is often left unexamined. In this Viewpoint, we introduce representational veracity (RV) as a companion concept to the Continuity Trap (CT) framework, grounded in a persistence-based account of representational adequacy developed in the parent framework manuscript. The Continuity Trap names the governance error in which a salient signal of continuity in one domain - technical, administrative, or infrastructural - is treated as sufficient evidence that ethical continuity has been preserved across all domains. In contrast, RV asks whether stored data continue to accurately and responsibly represent the persons, communities, and phenomena from which they were derived — at the point of use, not merely the point of collection. We draw on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health artificial-intelligence (AI) governance to show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, unstable, or normatively misdirected for the proposed use. Our analysis proceeds through the four-domain representational-veracity architecture (material provenance, informational descriptors, normative authorization, relational community), examines four recurrent failure modes (proxy substitution, category misassignment, label-generation error, descriptor sedimentation), and applies these to a polygenic risk score (PRS) use case. Our argument is not that existing governance mechanisms are wrong but that they need an additional upstream layer. Investigators should be required to justify not only whether their models perform, but also whether their representations are truthful enough for the clinical, public health, or policy claims at hand.
- 26 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessRepresentational Veracity in Data Science Health Research: A Companion Viewpoint on Targets, Proxies, Labels, and Descriptors (Preprint)
UNSTRUCTURED Prevailing ethical oversight of data science health research concentrates on privacy, consent, bias, and fairness. These concerns are necessary but insufficient, because they presuppose that the targets, proxies, labels, classifications, ontologies, and population descriptors already truthfully represent the populations and phenomena they claim to describe. That prior question is often left unexamined. In this Viewpoint, we introduce representational veracity (RV) as a companion concept to the Continuity Trap (CT) framework, grounded in a persistence-based account of representational adequacy developed in the parent framework manuscript. The Continuity Trap names the governance error in which a salient signal of continuity in one domain - technical, administrative, or infrastructural - is treated as sufficient evidence that ethical continuity has been preserved across all domains. In contrast, RV asks whether stored data continue to accurately and responsibly represent the persons, communities, and phenomena from which they were derived — at the point of use, not merely the point of collection. We draw on scholarship in quantification, classification, measurement, critical data studies, algorithmic fairness, and health artificial-intelligence (AI) governance to show that a model may be accurate, reproducible, and formally fair while resting on a representation that is too thin, unstable, or normatively misdirected for the proposed use. Our analysis proceeds through the four-domain representational-veracity architecture (material provenance, informational descriptors, normative authorization, relational community), examines four recurrent failure modes (proxy substitution, category misassignment, label-generation error, descriptor sedimentation), and applies these to a polygenic risk score (PRS) use case. Our argument is not that existing governance mechanisms are wrong but that they need an additional upstream layer. Investigators should be required to justify not only whether their models perform, but also whether their representations are truthful enough for the clinical, public health, or policy claims at hand.
- Open Access
- 1 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Dissolution of Continuity of Ethical Governance in Data Science Health Research: A Diagnostic and Response Framework for Lifecycle Oversight (Preprint)
UNSTRUCTURED Background: Traditional research ethics governance was built for bounded protocols, identifiable investigators, and temporally limited encounters with human participants. Data science health research (DSHR) disrupts that architecture because health data, biological materials, computational representations, and models persist, travel, combine, and acquire new uses across time. The ethical problem is not simply that individual instruments such as consent forms, IRB approvals, data access agreements, model cards, or privacy notices become outdated. It is that, across the lifecycle, the authorities that make these instruments ethically meaningful may lose jurisdiction, standing, evidentiary force, or remedial control. Conceptual contribution: This paper introduces Ethical Governance Continuity Dissolution (EGCD): the progressive and sometimes irreversible loss of domain-specific governance authority across a data, model, or biological-material lineage, such that no coherent assemblage of actors, instruments, rules, or community processes can any longer authorize, constrain, monitor, adjudicate, or remediate current use. EGCD differs from consent staleness, function creep, contextual integrity violations, algorithmic drift, and the continuity trap because it names the systemic condition in which several such failures become mutually reinforcing. Framework: Building on prior work on representational veracity and the continuity trap, we develop a six-domain authority taxonomy, diagnostic criteria, staging categories, and a prototype Ethical Continuity Dissolution Score. We then propose an Ethical Continuity Governance and Response Mechanism consisting of a continuity registry, continuity authority matrix, trigger-based lifecycle review, a Data Lifecycle Governance Officer, a Continuity Dissolution Review Board, cross-institutional audits, and community governance integration. Implications: EGCD provides a practical vocabulary and governance architecture for diagnosing and managing the loss of ethical governance continuity in global DSHR. The goal is not to freeze all original consent conditions indefinitely, but to prevent silent loss of governance authority as data, models, and biological materials move through increasingly complex research and translational ecosystems.
- 1 May 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDissolution of Continuity of Ethical Governance in Data Science Health Research: A Diagnostic and Response Framework for Lifecycle Oversight (Preprint)
UNSTRUCTURED Background: Traditional research ethics governance was built for bounded protocols, identifiable investigators, and temporally limited encounters with human participants. Data science health research (DSHR) disrupts that architecture because health data, biological materials, computational representations, and models persist, travel, combine, and acquire new uses across time. The ethical problem is not simply that individual instruments such as consent forms, IRB approvals, data access agreements, model cards, or privacy notices become outdated. It is that, across the lifecycle, the authorities that make these instruments ethically meaningful may lose jurisdiction, standing, evidentiary force, or remedial control. Conceptual contribution: This paper introduces Ethical Governance Continuity Dissolution (EGCD): the progressive and sometimes irreversible loss of domain-specific governance authority across a data, model, or biological-material lineage, such that no coherent assemblage of actors, instruments, rules, or community processes can any longer authorize, constrain, monitor, adjudicate, or remediate current use. EGCD differs from consent staleness, function creep, contextual integrity violations, algorithmic drift, and the continuity trap because it names the systemic condition in which several such failures become mutually reinforcing. Framework: Building on prior work on representational veracity and the continuity trap, we develop a six-domain authority taxonomy, diagnostic criteria, staging categories, and a prototype Ethical Continuity Dissolution Score. We then propose an Ethical Continuity Governance and Response Mechanism consisting of a continuity registry, continuity authority matrix, trigger-based lifecycle review, a Data Lifecycle Governance Officer, a Continuity Dissolution Review Board, cross-institutional audits, and community governance integration. Implications: EGCD provides a practical vocabulary and governance architecture for diagnosing and managing the loss of ethical governance continuity in global DSHR. The goal is not to freeze all original consent conditions indefinitely, but to prevent silent loss of governance authority as data, models, and biological materials move through increasingly complex research and translational ecosystems.